Autologous therapy for Parkinson’s disease: single cell RNAseq for in depth characterization of transplanted cells

  • Post author:
  • Post category:

Research Objective We are developing a durable patient-specific dopamine neuron replacement therapy for Parkinson's disease Impact Parkinson's disease is diagnosed when half of the dopamine (DA) neurons are lost from…

Continue ReadingAutologous therapy for Parkinson’s disease: single cell RNAseq for in depth characterization of transplanted cells

A tool for rapid development of clinical-grade protocols for dopaminergic neuronal differentiation of Parkinson’s Disease patient-derived iPSCs

  • Post author:
  • Post category:

Research Objective Develop a tool that facilitates rapid, cost effective development of optimized GMP-grade hPSC differentiation into functional DA neurons and apply this device to a cohort of PD patient-derived…

Continue ReadingA tool for rapid development of clinical-grade protocols for dopaminergic neuronal differentiation of Parkinson’s Disease patient-derived iPSCs

Microenvironment based optimization of retinal induction using CRISPR-CAS9 reporter pluripotent stem cells as an expandable source of retinal progenitors and photoreceptors.

  • Post author:
  • Post category:

Research Objective To increase the efficiency of generating pure retinal progenitor cultures for use in transplantation and to probe general aspects of retinal development. Impact Our methods could increase the…

Continue ReadingMicroenvironment based optimization of retinal induction using CRISPR-CAS9 reporter pluripotent stem cells as an expandable source of retinal progenitors and photoreceptors.

Development of a low-cost, clinical-grade iPS maintenance medium for enabling stem cell therapy manufacturing

  • Post author:
  • Post category:

Translational Candidate HiDef-B8, an iPS cell maintenance medium designed to reduce stem cell GMP manufacturing costs and risk. Area of Impact HiDef-B8 addresses scale-up manufacturing, by being lower-cost ($300/L) and…

Continue ReadingDevelopment of a low-cost, clinical-grade iPS maintenance medium for enabling stem cell therapy manufacturing